---
document_datetime: 2025-11-23 08:02:32
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/halimatoz.html
document_name: halimatoz.html
version: success
processing_time: 0.1069145
conversion_datetime: 2025-12-27 23:26:46.683002
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Halimatoz

[RSS](/en/individual-human-medicine.xml/65687)

##### Withdrawn

This medicine's authorisation has been withdrawn

adalimumab

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Halimatoz](#news-on)
- [Related content](#related-content-500)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 18 December 2020, the European Commission withdrew the marketing authorisation for Halimatoz (adalimumab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Sandoz GmbH, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Halimatoz was granted marketing authorisation in the EU on 26 July 2018 for treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, uveitis and paediatric uveitis. The marketing authorisation was initially valid for a 5-year period. The product has never been marketed in the EU.

Halimatoz is a biosimilar of Humira. There are other biosimilar medicinal products of Humira authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Halimatoz is updated to indicate that the marketing authorisation is no longer valid.

Halimatoz : EPAR - Medicine overview

Reference Number: EMA/509804/2018

English (EN) (671.76 KB - PDF)

**First published:** 03/08/2018

**Last updated:** 29/01/2021

[View](/en/documents/overview/halimatoz-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-561)

български (BG) (1.48 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/bg/documents/overview/halimatoz-epar-medicine-overview_bg.pdf)

español (ES) (671.96 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/es/documents/overview/halimatoz-epar-medicine-overview_es.pdf)

čeština (CS) (748.71 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/cs/documents/overview/halimatoz-epar-medicine-overview_cs.pdf)

dansk (DA) (669.35 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/da/documents/overview/halimatoz-epar-medicine-overview_da.pdf)

Deutsch (DE) (675.02 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/de/documents/overview/halimatoz-epar-medicine-overview_de.pdf)

eesti keel (ET) (668.26 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/et/documents/overview/halimatoz-epar-medicine-overview_et.pdf)

ελληνικά (EL) (778.97 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/el/documents/overview/halimatoz-epar-medicine-overview_el.pdf)

français (FR) (673.49 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/fr/documents/overview/halimatoz-epar-medicine-overview_fr.pdf)

hrvatski (HR) (690.17 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/hr/documents/overview/halimatoz-epar-medicine-overview_hr.pdf)

italiano (IT) (670.13 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/it/documents/overview/halimatoz-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (746.61 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/lv/documents/overview/halimatoz-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (699.05 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/lt/documents/overview/halimatoz-epar-medicine-overview_lt.pdf)

magyar (HU) (740.91 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/hu/documents/overview/halimatoz-epar-medicine-overview_hu.pdf)

Malti (MT) (750.99 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/mt/documents/overview/halimatoz-epar-medicine-overview_mt.pdf)

Nederlands (NL) (671.74 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/nl/documents/overview/halimatoz-epar-medicine-overview_nl.pdf)

polski (PL) (745.58 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/pl/documents/overview/halimatoz-epar-medicine-overview_pl.pdf)

português (PT) (671.69 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/pt/documents/overview/halimatoz-epar-medicine-overview_pt.pdf)

română (RO) (698.96 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/ro/documents/overview/halimatoz-epar-medicine-overview_ro.pdf)

slovenčina (SK) (748.62 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/sk/documents/overview/halimatoz-epar-medicine-overview_sk.pdf)

slovenščina (SL) (739.87 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/sl/documents/overview/halimatoz-epar-medicine-overview_sl.pdf)

Suomi (FI) (668.83 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/fi/documents/overview/halimatoz-epar-medicine-overview_fi.pdf)

svenska (SV) (670.17 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/sv/documents/overview/halimatoz-epar-medicine-overview_sv.pdf)

Halimatoz : EPAR - Risk-management-plan summary

English (EN) (695.34 KB - PDF)

**First published:** 03/08/2018

**Last updated:** 29/01/2021

[View](/en/documents/rmp-summary/halimatoz-epar-risk-management-plan-summary_en.pdf)

## Product information

Halimatoz : EPAR - Product Information

English (EN) (3.43 MB - PDF)

**First published:** 03/08/2018

**Last updated:** 29/01/2021

[View](/en/documents/product-information/halimatoz-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-761)

български (BG) (6.96 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/bg/documents/product-information/halimatoz-epar-product-information_bg.pdf)

español (ES) (3.05 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/es/documents/product-information/halimatoz-epar-product-information_es.pdf)

čeština (CS) (5.6 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/cs/documents/product-information/halimatoz-epar-product-information_cs.pdf)

dansk (DA) (3.03 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/da/documents/product-information/halimatoz-epar-product-information_da.pdf)

Deutsch (DE) (3.2 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/de/documents/product-information/halimatoz-epar-product-information_de.pdf)

eesti keel (ET) (2.94 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/et/documents/product-information/halimatoz-epar-product-information_et.pdf)

ελληνικά (EL) (6.91 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/el/documents/product-information/halimatoz-epar-product-information_el.pdf)

français (FR) (3.12 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/fr/documents/product-information/halimatoz-epar-product-information_fr.pdf)

hrvatski (HR) (2.59 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/hr/documents/product-information/halimatoz-epar-product-information_hr.pdf)

íslenska (IS) (3 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/is/documents/product-information/halimatoz-epar-product-information_is.pdf)

italiano (IT) (2.61 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/it/documents/product-information/halimatoz-epar-product-information_it.pdf)

latviešu valoda (LV) (5.7 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/lv/documents/product-information/halimatoz-epar-product-information_lv.pdf)

lietuvių kalba (LT) (3.28 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/lt/documents/product-information/halimatoz-epar-product-information_lt.pdf)

magyar (HU) (5.49 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/hu/documents/product-information/halimatoz-epar-product-information_hu.pdf)

Malti (MT) (5.72 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/mt/documents/product-information/halimatoz-epar-product-information_mt.pdf)

Nederlands (NL) (3 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/nl/documents/product-information/halimatoz-epar-product-information_nl.pdf)

norsk (NO) (2.95 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/no/documents/product-information/halimatoz-epar-product-information_no.pdf)

polski (PL) (5.73 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/pl/documents/product-information/halimatoz-epar-product-information_pl.pdf)

português (PT) (2.99 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/pt/documents/product-information/halimatoz-epar-product-information_pt.pdf)

română (RO) (3.5 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/ro/documents/product-information/halimatoz-epar-product-information_ro.pdf)

slovenčina (SK) (5.46 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/sk/documents/product-information/halimatoz-epar-product-information_sk.pdf)

slovenščina (SL) (5.35 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/sl/documents/product-information/halimatoz-epar-product-information_sl.pdf)

Suomi (FI) (3.05 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/fi/documents/product-information/halimatoz-epar-product-information_fi.pdf)

svenska (SV) (2.95 MB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/sv/documents/product-information/halimatoz-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IG/1290 18/12/2020

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Halimatoz : EPAR - All Authorised presentations

English (EN) (605.03 KB - PDF)

**First published:** 03/08/2018

**Last updated:** 29/01/2021

[View](/en/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-67)

български (BG) (699.15 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/bg/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_bg.pdf)

español (ES) (601.9 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/es/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_es.pdf)

čeština (CS) (655.17 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/cs/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (602.05 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/da/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (600.63 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/de/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (593.85 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/et/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (671.52 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/el/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_el.pdf)

français (FR) (602.29 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/fr/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (609.78 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/hr/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (601.31 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/is/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_is.pdf)

italiano (IT) (602.13 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/it/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (659.46 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/lv/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (621.42 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/lt/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (652.51 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/hu/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (657.56 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/mt/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (601.59 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/nl/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (602.11 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/no/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_no.pdf)

polski (PL) (655.51 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/pl/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_pl.pdf)

português (PT) (601.92 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/pt/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_pt.pdf)

română (RO) (624.72 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/ro/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (654.53 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/sk/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (649.9 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/sl/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (600.31 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/fi/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (601.94 KB - PDF)

**First published:**

03/08/2018

**Last updated:**

29/01/2021

[View](/sv/documents/all-authorised-presentations/halimatoz-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Halimatoz Active substance adalimumab International non-proprietary name (INN) or common name adalimumab Therapeutic area (MeSH)

- Hidradenitis Suppurativa
- Psoriasis
- Arthritis, Juvenile Rheumatoid
- Uveitis
- Arthritis, Rheumatoid
- Spondylitis, Ankylosing
- Arthritis, Psoriatic

Anatomical therapeutic chemical (ATC) code L04AB04

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

**Rheumatoid arthritis**

Halimatoz in combination with methotrexate, is indicated for:

- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.
- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.

Halimatoz can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.

**Juvenile idiopathic arthritis**

- Polyarticular juvenile idiopathic arthritis

Halimatoz in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Halimatoz can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.

- Enthesitis-related arthritis

Halimatoz is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy.

**Axial spondyloarthritis**

- Ankylosing spondylitis (AS)

Halimatoz is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.

- Axial spondyloarthritis without radiographic evidence of AS

Halimatoz is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and / or MRI, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs.

**Psoriatic arthritis**

Halimatoz is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.

Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function.

**Psoriasis**

Halimatoz is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.

- Paediatric plaque psoriasis

Halimatoz is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.

**Hidradenitis suppurativa (HS)**

Halimatoz is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy.

**Crohn's disease**

Halimatoz is indicated for treatment of moderately to severely active Crohn's disease in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and / or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.

- Paediatric Crohn's disease

Halimatoz is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and / or an immunomodulator, or who are intolerant to or have contraindications for such therapies.

- Ulcerative colitis/ Uveitis/ Paediatric uveitis

For full indication see 4.1.

## Authorisation details

EMA product number EMEA/H/C/004866

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Sandoz GmbH

Biochemiestrasse 10

Opinion adopted 31/05/2018 Marketing authorisation issued 26/07/2018 Withdrawal of marketing authorisation 18/12/2020 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Halimatoz : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (810.88 KB - PDF)

**First published:** 03/12/2018

**Last updated:** 29/01/2021

[View](/en/documents/procedural-steps-after/halimatoz-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Halimatoz : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/519681/2018

English (EN) (4.65 MB - PDF)

**First published:** 03/08/2018

**Last updated:** 29/01/2021

[View](/en/documents/assessment-report/halimatoz-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Halimatoz

Adopted

Reference Number: EMA/CHMP/241919/2018

English (EN) (689.92 KB - PDF)

**First published:** 01/06/2018

**Last updated:** 29/01/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-halimatoz_en.pdf)

#### News on Halimatoz

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 May 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-may-2018) 01/06/2018

#### Related content

- [Biosimilar medicines](/en/human-regulatory/overview/biosimilar-medicines)

**This page was last updated on** 29/01/2021

## Share this page

[Back to top](#main-content)